ISLR and triple-negative breast carcinoma: As previous reports have demonstrated that cisplatin can induce oxidative stress [31], to determine whether ISLR can respond to cisplatin treatment in triple-negative breast cancer in vivo, we transplanted 4T1 cells into Balb/c mice and found that cisplatin treatment significantly reduced ISLR protein in the tumor tissue (Figure 6A), demonstrating that ISLR can respond to cisplatin treatment in triple-negative breast cancer in vivo.